within Pharmacolibrary.Drugs.ATC.V;

model V09IX17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 13 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.042,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>PSMA-1007 labeled with fluorine-18 is a radiopharmaceutical used in positron emission tomography (PET) imaging for the detection of prostate-specific membrane antigen (PSMA)–positive prostate cancer lesions. It is not used as a therapeutic agent but as a diagnostic tracer, approved for clinical use in numerous countries for prostate cancer imaging.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data in adult male patients with prostate cancer undergoing PET imaging after intravenous injection.</p><h4>References</h4><ol><li><p>Kim, SB, et al., &amp; Kim, SE (2023). Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [. <i>Molecular pharmaceutics</i> 20(2) 1050–1060. DOI:<a href=&quot;https://doi.org/10.1021/acs.molpharmaceut.2c00788&quot;>10.1021/acs.molpharmaceut.2c00788</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36583623/&quot;>https://pubmed.ncbi.nlm.nih.gov/36583623</a></p></li><li><p>Aras, O, et al., &amp; Sayman, HB (2021). Small Molecule, Multimodal, [. <i>Clinical genitourinary cancer</i> 19(5) 405–416. DOI:<a href=&quot;https://doi.org/10.1016/j.clgc.2021.03.011&quot;>10.1016/j.clgc.2021.03.011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33879400/&quot;>https://pubmed.ncbi.nlm.nih.gov/33879400</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V09IX17;
